Armata Pharmaceuticals, Inc. (ARMP)
USD 1.95
(-2.5%)
USD 1.95
(-2.5%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.52 Million USD | -17.77% |
| 2022 | 5.5 Million USD | 23.11% |
| 2021 | 4.47 Million USD | 443.62% |
| 2020 | 823 Thousand USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 115 Thousand USD | -55.77% |
| 2016 | 260 Thousand USD | -45.26% |
| 2015 | 475 Thousand USD | 16.14% |
| 2014 | 409 Thousand USD | 25.85% |
| 2013 | 325 Thousand USD | -51.05% |
| 2012 | 664 Thousand USD | 0.0% |
| 2008 | 8.71 Million USD | -15.62% |
| 2007 | 10.33 Million USD | 4.74% |
| 2006 | 9.86 Million USD | 43.5% |
| 2005 | 6.87 Million USD | -28.78% |
| 2004 | 9.65 Million USD | -31.41% |
| 2003 | 14.07 Million USD | -27.21% |
| 2002 | 19.33 Million USD | 2.4% |
| 2001 | 18.88 Million USD | 65.57% |
| 2000 | 11.4 Million USD | 67.69% |
| 1999 | 6.8 Million USD | -5.56% |
| 1998 | 7.2 Million USD | 700.0% |
| 1997 | 900 Thousand USD | -60.87% |
| 1996 | 2.3 Million USD | 2200.0% |
| 1995 | 100 Thousand USD | -75.0% |
| 1994 | 400 Thousand USD | 300.0% |
| 1993 | 100 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 966 Thousand USD | -36.78% |
| 2024 Q2 | - USD | -100.0% |
| 2023 FY | 4.52 Million USD | -17.77% |
| 2023 Q1 | 796 Thousand USD | -24.26% |
| 2023 Q2 | 980 Thousand USD | 23.12% |
| 2023 Q4 | 1.52 Million USD | 24.73% |
| 2023 Q3 | 1.22 Million USD | 25.0% |
| 2022 Q2 | 1.88 Million USD | 0.0% |
| 2022 FY | 5.5 Million USD | 23.11% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q4 | 1.05 Million USD | -21.45% |
| 2022 Q3 | 1.33 Million USD | -28.94% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q1 | 1.06 Million USD | 3538.71% |
| 2021 Q2 | - USD | -100.0% |
| 2021 FY | 4.47 Million USD | 443.62% |
| 2020 Q2 | 31 Thousand USD | 0.0% |
| 2020 Q3 | - USD | -100.0% |
| 2020 Q4 | -31 Thousand USD | 0.0% |
| 2020 FY | 823 Thousand USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | -100.0% |
| 2017 Q2 | 28 Thousand USD | -3.45% |
| 2017 Q4 | 20 Thousand USD | -47.37% |
| 2017 Q1 | 29 Thousand USD | 31.82% |
| 2017 FY | 115 Thousand USD | -55.77% |
| 2017 Q3 | 38 Thousand USD | 35.71% |
| 2016 Q1 | 106 Thousand USD | -17.19% |
| 2016 FY | 260 Thousand USD | -45.26% |
| 2016 Q3 | 29 Thousand USD | -71.84% |
| 2016 Q4 | 22 Thousand USD | -24.14% |
| 2016 Q2 | 103 Thousand USD | -2.83% |
| 2015 Q3 | 143 Thousand USD | 40.2% |
| 2015 Q2 | 102 Thousand USD | 0.0% |
| 2015 Q1 | 102 Thousand USD | 3.03% |
| 2015 FY | 475 Thousand USD | 16.14% |
| 2015 Q4 | 128 Thousand USD | -10.49% |
| 2014 Q2 | 310 Thousand USD | -99.7% |
| 2014 Q3 | 103 Million USD | 33125.81% |
| 2014 Q4 | 99 Thousand USD | -99.9% |
| 2014 FY | 409 Thousand USD | 25.85% |
| 2014 Q1 | 104 Million USD | 1300100.0% |
| 2013 Q3 | -3000.00 USD | -100.96% |
| 2013 Q4 | -8000.00 USD | -166.67% |
| 2013 Q2 | 314 Thousand USD | 1327.27% |
| 2013 Q1 | 22 Thousand USD | 0.0% |
| 2013 FY | 325 Thousand USD | -51.05% |
| 2012 FY | 664 Thousand USD | 0.0% |
| 2009 Q1 | 2.02 Million USD | -9.78% |
| 2009 Q2 | 3.36 Million USD | 66.35% |
| 2009 Q3 | 3.71 Million USD | 10.38% |
| 2008 Q3 | 1.74 Million USD | -22.13% |
| 2008 FY | 8.71 Million USD | -15.62% |
| 2008 Q4 | 2.24 Million USD | 28.59% |
| 2008 Q1 | 2.49 Million USD | -22.39% |
| 2008 Q2 | 2.23 Million USD | -10.48% |
| 2007 Q1 | 1.66 Million USD | -58.56% |
| 2007 Q2 | 3 Million USD | 81.1% |
| 2007 Q3 | 2.44 Million USD | -18.78% |
| 2007 Q4 | 3.22 Million USD | 31.81% |
| 2007 FY | 10.33 Million USD | 4.74% |
| 2006 Q1 | 2.43 Million USD | 25.0% |
| 2006 Q2 | 1.41 Million USD | -41.81% |
| 2006 Q4 | 4 Million USD | 99.2% |
| 2006 Q3 | 2.01 Million USD | 42.29% |
| 2006 FY | 9.86 Million USD | 43.5% |
| 2005 Q2 | 1.46 Million USD | -26.9% |
| 2005 FY | 6.87 Million USD | -28.78% |
| 2005 Q3 | 1.46 Million USD | 0.41% |
| 2005 Q1 | 2 Million USD | -37.17% |
| 2005 Q4 | 1.94 Million USD | 32.43% |
| 2004 Q3 | 2.38 Million USD | -13.51% |
| 2004 Q4 | 3.18 Million USD | 33.29% |
| 2004 Q1 | 1.32 Million USD | -4.28% |
| 2004 Q2 | 2.76 Million USD | 109.17% |
| 2004 FY | 9.65 Million USD | -31.41% |
| 2003 Q2 | 2.05 Million USD | -63.59% |
| 2003 Q4 | 1.37 Million USD | -72.43% |
| 2003 FY | 14.07 Million USD | -27.21% |
| 2003 Q1 | 5.63 Million USD | 23.99% |
| 2003 Q3 | 5 Million USD | 143.64% |
| 2002 FY | 19.33 Million USD | 2.4% |
| 2002 Q1 | 5.37 Million USD | 3.31% |
| 2002 Q2 | 4.59 Million USD | -14.47% |
| 2002 Q3 | 4.82 Million USD | 4.99% |
| 2002 Q4 | 4.54 Million USD | -5.68% |
| 2001 Q3 | 5.53 Million USD | 27.65% |
| 2001 Q4 | 5.19 Million USD | -6.15% |
| 2001 Q2 | 4.33 Million USD | 14.01% |
| 2001 Q1 | 3.8 Million USD | 236.05% |
| 2001 FY | 18.88 Million USD | 65.57% |
| 2000 Q3 | 6.34 Million USD | 261.91% |
| 2000 FY | 11.4 Million USD | 67.69% |
| 2000 Q4 | 1.13 Million USD | -82.15% |
| 2000 Q2 | 1.75 Million USD | -19.42% |
| 2000 Q1 | 2.17 Million USD | -22.32% |
| 1999 FY | 6.8 Million USD | -5.56% |
| 1999 Q1 | 1.3 Million USD | -81.69% |
| 1999 Q2 | 1.5 Million USD | 15.38% |
| 1999 Q3 | 1.4 Million USD | -6.67% |
| 1999 Q4 | 2.8 Million USD | 100.0% |
| 1998 Q2 | 200 Thousand USD | -33.33% |
| 1998 Q4 | 7.1 Million USD | 2266.67% |
| 1998 Q3 | 300 Thousand USD | 50.0% |
| 1998 Q1 | 300 Thousand USD | 200.0% |
| 1998 FY | 7.2 Million USD | 700.0% |
| 1997 Q3 | 800 Thousand USD | 166.67% |
| 1997 Q1 | 400 Thousand USD | -73.33% |
| 1997 FY | 900 Thousand USD | -60.87% |
| 1997 Q4 | 100 Thousand USD | -87.5% |
| 1997 Q2 | 300 Thousand USD | -25.0% |
| 1996 FY | 2.3 Million USD | 2200.0% |
| 1996 Q4 | 1.5 Million USD | 87.5% |
| 1996 Q3 | 800 Thousand USD | 700.0% |
| 1996 Q1 | 200 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | -50.0% |
| 1995 Q3 | 100 Thousand USD | 0.0% |
| 1995 Q4 | - USD | -100.0% |
| 1995 FY | 100 Thousand USD | -75.0% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q4 | 100 Thousand USD | -50.0% |
| 1994 FY | 400 Thousand USD | 300.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q3 | 200 Thousand USD | 100.0% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 FY | 100 Thousand USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 202 Thousand USD | -2142.079% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Actinium Pharmaceuticals, Inc. | 81 Thousand USD | -5491.358% |
| Azitra, Inc. | 686 Thousand USD | -560.204% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | -509.556% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
| CEL-SCI Corporation | - USD | -Infinity% |
| iBio, Inc. | 225 Thousand USD | -1912.889% |
| Lineage Cell Therapeutics, Inc. | 8.94 Million USD | 49.368% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 1.09 Million USD | -313.23% |
| Navidea Biopharmaceuticals, Inc. | 65.65 Thousand USD | -6798.495% |
| NovaBay Pharmaceuticals, Inc. | 14.72 Million USD | 69.245% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 37.65 Thousand USD | -11928.258% |
| BiomX Inc. | -357 Thousand USD | 1368.627% |
| BiomX Inc. | -357 Thousand USD | 1368.627% |
| Protalix BioTherapeutics, Inc. | 65.49 Million USD | 93.085% |
| Palatin Technologies, Inc. | 4.49 Million USD | -0.867% |
| Scorpius Holdings, Inc. | 6.99 Million USD | 35.252% |